• FDA expands Xtandi approval for prostate cancer

    3 monthes ago - By Healio

    The FDA expanded the approval of enzalutamide to include the treatment of nonmetastatic castration-resistant prostate cancer.
    Enzalutamide - an androgen receptor inhibitor - received FDA approval in 2012 for the treatment of men with metastatic castration-resistant prostate cancer who previously received docetaxel. In 2014, the FDA approved enzalutamide for chemotherapy-naive men with metastatic castration-resistant prostate cancer.
    With the newest approval, enzalutamide becomes the only oral treatment to receive FDA approval for both nonmetastatic and
    Read more ...